DBV Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
DBV Technologies S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.63 |
| 52 Week High | €1.83 |
| 52 Week Low | €0.44 |
| Beta | 0.86 |
| 11 Month Change | -20.58% |
| 3 Month Change | -16.16% |
| 1 Year Change | -55.86% |
| 33 Year Change | -87.52% |
| 5 Year Change | -95.51% |
| Change since IPO | -92.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| DBV | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 35.1% | -1.1% | 1.1% |
| 1Y | -55.9% | -18.8% | 7.2% |
Return vs Industry: DBV underperformed the German Biotechs industry which returned -18.3% over the past year.
Return vs Market: DBV underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| DBV volatility | |
|---|---|
| DBV Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DBV's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: DBV's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 108 | Daniel Tassé | www.dbv-technologies.com |
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
DBV Technologies S.A. Fundamentals Summary
| DBV fundamental statistics | |
|---|---|
| Market cap | €63.11m |
| Earnings (TTM) | -€96.63m |
| Revenue (TTM) | €11.85m |
5.3x
P/S Ratio-0.7x
P/E RatioIs DBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DBV income statement (TTM) | |
|---|---|
| Revenue | US$12.52m |
| Cost of Revenue | US$0 |
| Gross Profit | US$12.52m |
| Other Expenses | US$114.60m |
| Earnings | -US$102.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 100.00% |
| Net Profit Margin | -815.73% |
| Debt/Equity Ratio | 0% |
How did DBV perform over the long term?
See historical performance and comparison